- Sangamo Therapeutics (NASDAQ:SGMO) has agreed to license its neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, to Eli Lilly (NYSE:LLY) for one goal to ship genomic drugs to deal with central nervous system illnesses.
- Sangamo is up ~28% in after-hours buying and selling Thursday.
- The
